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and in patients with type 2 diabetes 1～6）. The detailed 
mechanisms for the possible atherogenic effect of 
postprandial hyperglycemia are unknown. However, 
increased oxidative stress due to glucose fluctuations 7）
may be at least partially involved, because it is shown 
that oxidative stress has a critical role in the progres-
sion of diabetic complications 8,9）. Interestingly, vari-
ability in glycemic control due to alternating repeti-
tion of high and low glucose concentrations is more 
deleterious to endothelial cells than a constant high 
glucose concentration as demonstrated in an in-vitro 
study 10）. These findings support the hypothesis that 
treatment that inhibits postprandial hyperglycemia 
using short-acting antidiabetic drugs is more benefi-
INTRODUCTION
Recent evidence suggests that postprandial plasma 
glucose（PPPG）or postchallenge plasma glucose as 
measured by a glucose-tolerance test may be more 
strongly related to cardiovascular events than fasting 
plasma glucose（FPG）levels in non-diabetic subjects 
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ABSTRACT
Aims：The goal of this study was to investigate the effect of switching from either the low dose sulfo-
nylurea glimepiride（1 mg once daily）or the glinide mitiglinide（10 mg three times daily）to repaglinide
（0.5 mg three times daily）on both glycemic control and oxidative stress in patients with type 2 diabetes.
Patients and Methods：Finally 17 patients（patients treated with either glimepiride：n＝11 or miti-
glinide：n＝6）completed the study. The type and dose of all drugs, including the anti-diabetic treatments, 
were not changed for at least 1 month prior to the study.
Results：Both groups showed a significant decrease in HbA1c levels. FPG showed a tendency（not sig-
nificant）toward a decrease in the mitiglinide-treated group, while no change was found in the glimepiride-
treated group. A significant decrease in 8-iso-PGF2a  levels was found only in the glimepiride-treated 
group. There was a significant correlation between the difference in 8-iso-PGF2a  levels and that in either 
FPG or HbA1c before and after the switch only in the mitiglinide-treated group.
Conclusions：Repaglinide may have an anti-oxidative effect probably due to the strong postprandial glu-
cose lowering observed in patients with type 2 diabetes.
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cial for the inhibition of the progression of cardiovas-
cular disease compared to that which decreases the 
overall glucose concentration（including FPG）using 
long-acting antidiabetic drugs. This is due to the 
expected decrease of oxidative stress by short-acting 
anti-diabetic drugs even if the overall glucose-lower-
ing effect ［as evaluated by hemoglobin（HbA1c）］ of 
these drugs is similar.
The glinides, oral hypoglycemic agents that stimu-
late insulin secretion by pancreatic beta cells by 
reversibly blocking ATP-sensitive potassium chan-
nels, have similar activity to sulfonylureas. However, 
because the effect is short-acting compared to that of 
sulfonylureas, glinides are categorized as short-acting 
hypoglycemic agents for mainly postprandial hyper-
glycemia. Therefore, it is speculated that glinides may 
decrease oxidative stress and may inhibit the progres-
sion of atherosclerosis in patients with type 2 diabetes. 
In fact, in both an animal study and a clinical study 
with a small number of patients, the anti-oxidative 
effect of glinides was reported 11～13）. Furthermore, it 
was reported that improvement of postprandial 
hyperglycemia was associated with regression of 
carotid intima-media thickness（IMT）by the adminis-
tration of glinides（but not by administration of sulfo-
nylureas）14）.
Repaglinide, a glinide, has been suggested to have a 
stronger overall glucose-lowering effect compared 
with that of other glinides, such as nateglinide 15）. The 
strength of the glucose-lowering effect is equal to that 
of a normal dose of sulfonylureas 14）. Thus, the switch 
from either low dose-sulfonylureas or other glinides 
to repaglinide may more effectively improve glycemic 
control, and may decrease the oxidative stress by 
more significantly reducing postprandial glucose lev-
els.
Based on this information, we investigated in the 
current study the effect of switching from a low dose 
of the sulfonylurea glimepiride（1 mg once daily）or 
the glinide mitiglinide（10 mg three times daily）to 
repaglinide（0.5 mg three times daily）on glycemic 
control and oxidative stress. We evaluated this switch 
based on urinary 8-iso-prostaglandin（PG）F2a  levels, 
which is one of the representative markers of system-
ic oxidative stress 16）. We hypothesized that the switch 
to repaglinide from these drugs may result in an 
improvement in both oxidative stress and glycemic 
control.
PATIENTS AND METHODS
Patients
This was a prospective single-arm study. Patients 
with type 2 diabetes who had been treated with 
either glimepiride 1 mg once daily after breakfast or 
with mitiglinide 10 mg three times daily before each 
meal, were switched to repaglinide 0.5 mg three times 
daily before each meal.
The target number of patients was initially set as 
20, and the 20 patients were consecutively enrolled 
from February 2014 to May 2014（except 1 patient 
enrolled on December 2012）in our hospital. Finally 17 
patients（patients treated with either glimepiride：n＝
11 or mitiglinide：n＝6）completed the study. In the 
mitiglinide group, 1 patient discontinued within 3 
months after enrollment. In the glimepiride group, 2 
patients discontinued taking repaglinide because 1 
patient felt occasional nausea and the other patient 
felt mild leg cramps after switching to the drug.
Key inclusion criteria were 1）patients aged 20 or 
over, 2）patients diagnosed as type 2 diabetes accord-
ing to the Japan Diabetic Society Criteria 17）, 3）outpa-
tient status, 4）patients with 6.5％ and higher HbA1c 
levels, 5）patients with 0.5％ or less variation in their 
HbA1c levels 2 month prior to the study, 6）patients 
in whom the type and dose of all drugs, including 
anti-diabetic ones, did not change during at least 
1 month prior to the study, and 7）patients giving con-
sent in writing for participation in this study. Key 
exclusion criteria were 1）patients with severe ketosis, 
diabetic coma, or type 1 diabetes, 2）patients with 
severe infectious disease, within 1 month after sur-
gery, or having a severe traumatic injury, and 3）
patients otherwise judged as unacceptable for partici-
pation in this study by our medical doctor.
Clinical and laboratory tests showed no evidence of 
either liver dysfunction or autoimmune disease in any 
patients. The characteristics at baseline of the patients 
treated with glimepiride and with mitiglinide before 
the switch to repaglinide are shown in Table 1. We 
previously measured fasting urinary 8-iso-PGF2a  
levels in non-diabetic healthy subjects（9 men and 1 
woman）as a control. Their mean age, body mass 
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index（BMI）, and 8-iso-PGF2a  were 40.8±8.7 years, 
23.2±3.12 kg/m2, and 152.8±66.7 pg/g.Cr, respective-
ly.
METHODS
The primary outcomes of this study for each group 
were HbA1c levels, fasting plasma glucose（FPG）lev-
els, and urinary 8-iso-PGF2a  levels 3 months after 
starting the study. Key secondary outcomes for each 
group were fasting plasma insulin levels, HOMA-IR, 
HOMA-b , serum lipids, and urinary albumin excretion
（UAE）levels 3 months after starting the study.
Blood and urine were collected in the outpatient 
department from 8：30 to 9：30 a.m. after overnight 
fasting for at least 10 hr. The collected blood was 
immediately placed into specific test tubes for differ-
ent assays, and then rapidly centrifuged at 1,500 rpm 
for 5 minutes to separate the serum or plasma from 
the clot-containing blood cells. The samples for 8-iso-
PGF2a（urine）and insulin（plasma）analyses were 
stored frozen at −70° C until analysis.
Measurement of plasma glucose, hemoglobin（Hb）
A1c, and serum lipids. Fasting plasma glucose（FPG）
was evaluated immediately after blood collection using 
an automated glucose oxidase method（Glucose Auto 
Stat GA1160®；Arkray, Kyoto, Japan）. HbA1c was 
also measured immediately after blood collection in a 
test tube containing EDTA-2K using high-perfor-
mance lipid chromatography（HPLC；Hi-Auto A1c®, 
HA8150®；Arkray）. Only HbA1c is detected with 
this method, and the normal range is 4.5％ to 6.2％ 
［NGSP：national glycohemoglobin standardization 
program］. Serum total cholesterol（TC）, low-density 
lipoprotein cholesterol（LDL-C）, high-density lipopro-
tein cholesterol（HDL-C）, and serum triglyceride（TG）
were measured using enzymatic assays. The Deter-
miner L TC II® and Determiner L TG® reagents
（Kyowa Medics, Tokyo, Japan）were used for mea-
surements of TC and TG, respectively. HDL-C was 
measured directly by a method based on selective sol-
ubilization of different lipoproteins by proprietary 
detergents using Cholestest N HDL-C®（Daiichi Pure 
Chemicals, Tokyo, Japan）. LDL-C was also measured 
directly using Cholestest LDL®（Daiichi Pure Chemi-
cals）, rather than indirectly using the Friedwald equa-
tion. Plasma insulin was measured by a chemilumines-
cent enzyme immunoassay（CLEIA）using the 
lumipulse Presto Insulin Kit®（Fujirebio, Tokyo, 
Japan）.
Urinary 8-iso-PGF2a  assay. Urinary 8-iso-PGF2a  
Table 1　 Clinical characteristics at baseline of the patients changed from glimepiride or 
mitiglinide to repaglinide
Glimepiride Mitiglinide P
No.（male/female） 11（2/9） 6（4/2） ─
Age（year）  72.3±10.5  72.8±7.5 0.9098
BMI（kg/m2）  22.9±3.2  24.0±4.3 0.5653
FPG（mg/dL） 138.5±33.1 199.0±46.0 0.0067＊
HbA1c（％）   7.4±0.4   7.5±0.9 0.8131
Urinary 8-iso PGF2a（pg/g.Cr） 365.1±263.9 171.5±93.6 0.1064
Diabetic therapy
　DPP4-I 3 1 ─
　Metformin 1 1 ─
　AGI 2 1 ─
　DPP4-I, AGI 2 1 ─
　DPP4-I, metformin, pioglitazone 1 0 ─
　Diet alone 2 2 ─
Data are expressed as mean±standard deviation（SD）, Comparison in variables between 
two groups were made by use of an unpaired t test. P：p value, P＜0.05 are defined as 
statistical significance（＊）. BMI：body mass index, FPG fasting plasma glucose, 
HbA1c：hemoglobin A1c, 8-iso-PGFa：8-iso-plostaglandin F2a , DPP4-I：dipeptidyl 
peptidase（DPP）-4 inhibitors, AGI：a-glucosidase inhibitors.
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was measured on the first urine of the morning with 
an enzyme immunoassay（EIA）kit（ACE® EIA；Cay-
man Chemical Company, Ann Arbor, MI）with intra- 
and interassay CVs of less than 10％ , based on actual 
values. This assay has been reported to show no dif-
ferences between measurements of morning urine 
samples and urine samples stored for 24 hours 18）. 
Data were adjusted by urine creatinine concentra-
tions. It has been reported that urinary 8-iso-PGF2a  
levels can change during short-term treatment, such 
as 1-2 hours 19）.
Homeostasis model assessment-insulin resistance
（HOMA-IR）, and Homeostasis model assessment b
（HOMA-b）. HOMA-IR was used as an indicator of 
insulin resistance and was calculated as follows：
HOMA-IR＝FPG（mg/dL）× fasting immunoreactive 
insulin（µU/mL）/405. HOMA-b  was used as an indi-
cator of insulin secretion activity and was calculated 
as follows：HOMA-b＝360×fasting immunoreactive 
insulin（µU/mL）/fasting plasma glucose（mg/dL）-63.
Ethical considerations. All subjects gave informed 
consent for inclusion in the study. The study was 
approved by the Local Ethics Committee in Dokkyo 
Medical University Koshigaya Hospital and was per-
formed according to the guidelines of the Declaration 
of Helsinki.
Statistical methods. The two time points for each 
parameter for an individual were compared using a 
paired t-test. For 8-iso-PGF2a  and UAE, a Wilcoxon 
signed rank test was also used as a non-parametric 
test due to its skewed distributions. Comparisons 
between the two groups were made using an 
unpaired t-test for normally distributed data（con-
firmed by a c 2 test）. A Student t-test or a Welch 
t-test was chosen based on the homogeneity of vari-
ance calculated by an F-test. For multiple compari-
sons, the Bartlett test showed that there were no sig-
nificant differences in variance among the three 
groups. A parametric comparison was performed by 
one-way analysis of variance（ANOVA）. The ANOVA 
was significant. Therefore, the significance of the indi-
vidual differences was assessed using the Bonferroni 
test. A P value of less than 0.05 was accepted as indi-
cating statistical significance（two-sided）.
Table 2　Changes during 3 months in various variables by changing fro glimepiride or mitiglinide to repaglinide
Glimepiride（n＝11） Mitiglinide（n＝6）
Baseline 3 months P Baseline 3 months P
FPG（mg/dL） 138.5±33.0 141.5±33.1 0.7974 199.0±46.0 144.0±24.3 0.0910
HbA1c（％） 7.4±0.4 6.7±0.5 0.0004＊ 7.5±0.9 6.7±0.8 0.0034＊
TC（mg/dL） 184.3±15.3 181.8±33.4 0.7564 198.3±41.2 195.3±30.5 0.8358
TG（mg/dL） 117.7±65.5 118.5±61.2 0.9657 168.3±102.7 144.7±60.2 0.5655
HDL-C（mg/dL） 54.5±13.2 48.7±12.8 0.0392＊ 46.3±14.6 50.5±15.9 0.2299
LDL-C（mg/dL） 112.7±65.5 118.5±61.2 0.9657 113.3±26.3 109.3±18.7 0.5460
SBP（mmHg） 129.0±10.9 131.0±8.7 0.6364 125.3±8.5 118.3±26.2 0.5465
DBP（mmHg） a72.7±6.7 72.4± 6.1 0.9082 79.2±19.6 70.7±2.4 0.3492
Insulin（µU/mL） 13.3±11.5 9.3±4.0 0.2637 20.9±18.2 9.4±5.7 0.3299
UAE（mg/g.Cr） 246.6±375.9 242.1±471.3 0.9245（0.3980 A） 789.7±540.2 736.7±477.9 0.8379（1.000A）
HOMA-IR 4.9±5.0 3.2±1.6 0.3227 10.9±10.2 3.7±2.9 0.2977
HOMA-b 66.5±39.0 47.6±19.7 0.1034 55.2±43.2 38.2±10.1 0.5164
8-iso-PGF2a（pg/g.Cr） 365.1±263.9 323.6±239.5 0.0495＊（0.0454A） 171.5±93.6 159.8±48.6 0.8348（0.7532A）
Data are expressed as means±SD. P：p value for change before and after therapy by paired t test.
P＜0.05 are defined as statistically significant（＊）. A：P value calculated by Wilcoxon signed rank test.
FPG：fasting plasma glucose；HbA1c：hemoglobin A1c；TC：total cholesterol；TG：triglyceride；HDL-C：high-density 
lipoprotein cholesterol；LDL-C：low-density lipoprotein cholesterol；SBP：systolic blood pressure；DBP：diastolic blood 
pressure；UAE：urinary albumin excretion, HOMA-IR：homeostasis assessment insulin resistance, HOMA-b：homeostasis 
assessment b , 8-iso-PGF2a：8-iso-prostaglandin F2a . The number of patients in TC, insulin, UAE was respective 9, 9, 7 in 
glimepiride-treated group and respective 6, 4, 3 in mitiglinide-treated group.
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RESULTS
Although patients with 0.5％ or less variation of 
HbA1c levels in the 2 months prior to the study were 
intended to be included in this study as described in 
the inclusion criteria, 2 patients in the glimepiride-
treated group showed equal to or more than a 0.6％ 
variation of HbA1c levels. We decided to include 
these patients because of the relative small number of 
patients in this study. In these patients, The HbA1c 
levels at 2 months before the switch, at baseline and 
at 3 months after the switch were 6.8-7.9-7.6％ and 
6.9-7.5-6.5％ , respectively. Their 8-iso-PGF2a  levels 
at baseline and at 3 months after the switch were 
380-383 pg/g.Cr and 205-199 pg/g.Cr, respectively.
Changes in certain variables at baseline and at 3 
months in patient-groups treated with either 
glimepiride or mitiglinide before the switch to repa-
glinide are presented in Table 2 . A significant 
decrease was obtained in HbA1c levels in both groups
（Fig. 1）. FPG showed a tendency（no significance）
toward a decrease in the mitiglinide-treated group, 
Fig. 1A, B　 The changes in HbA1c by therapy changing from glimepiride（A）or 
mitiglinide（B）to repaglinide
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while no change was found in the glimepiride-treated 
group（Fig. 2）. A significant decrease in 8-iso-PGF2a  
was found in the glimepiride-treated group（Fig. 3）.
There was no significant change in SBP, DBP, 
serum lipids, insulin, and HOMA-IR in both groups, 
except for a significant decrease in HDL-C in the 
glimepiride-treated group. There was a tendency 
toward a decrease in HOMA-b  in the glimepiride-
treated group.
There was a significant difference in the 8-iso-
PGF2a  levels between the glimepiride-treated group 
at baseline and the healthy control group（Fig. 4）. 
The difference in 8-iso-PGF2a  was also significant 
between the glimepiride-treated group 3 months after 
the switch to repaglinide and the healthy control 
group.
There was a tendency toward a positive correlation
（no significance）between 8-iso-PGF2a  and FPG at 
baseline in both groups, but no correlation between 
8-iso-PGF2a  and HbA1c at baseline in both groups 
was observed（Table 3）.
There was significant positive correlation between 
the difference in 8-iso-PGF2a  and that in both FPG 
and HbA1c before and after the switch only in the 
mitiglinide-treated group（Table 3）.
DISCUSSION
In the current study, the switch from glimepiride 
1 mg once daily to repaglinide 0 .5 mg three times 
daily significantly decreased HbA1c levels during the 
3 month observation-period. This result basically sup-
ports previous reports showing the strong glucose-
lowering effect of repaglinide 14）. However, no signifi-
cant change was observed in FPG. The result appears 
to be reasonable because repaglinide is short-acting 
when compared with glimepiride, and therefore main-
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ly reduces postprandial plasma glucose（PPPG）, 
although this agent can decrease FPG to some 
degree 15）. In the current study, the PPPG levels were 
not evaluated；we chose FPG for our evaluation of 
glucose levels because we also intended to evaluate 
HOMA-IR and HOMA-b , which are calculated using 
FPG. However, given the fact that HbA1c levels were 
significantly decreased despite a similar effect for FPG 
by these drugs, it is speculated that PPPG was largely 
decreased by the switch to repaglinide. On the other 
hand, the switch from mitiglinide to repaglinide also 
significantly decreased the HbA1c levels as expected. 
There is a report written in Japanese demonstrating 
that repaglinide has an overall stronger glucose-low-
ering effect when compared with mitiglinide（refer-
ence is not shown）. Interestingly this change led to 
the tendency toward a decrease of FPG despite the 
fact that both drugs are short-acting, and further sup-
ports the mild FPG-lowing effect of repaglinide 15）.
As expected, the switch from glimepiride to repa-
glinide significantly decreased the 8-iso PGF2a  levels
（a marker of systemic oxidative stress）. It is reported 
that 8-iso PGF2a  levels positively correlate with the 
daily variation of plasma glucose levels evaluated by 
an index, such as mean amplitude of glycemic excur-
sions（MAGE）7）. Therefore, it may be possible that 
the results in this study were based on the speculated 
larger decrease of PPPG and consequently the greater 
reduction in variation of plasma glucose levels by rep-
aglinide compared with that of glimepiride. However, 
since the switch to repaglinide showed not only the 
speculated improvement in the glucose variation but 
also a decrease in HbA1c levels, the overall improve-
ment of glycemic control by repaglinide may have 
been partially due to the decrease in the 8-iso PGF2a  
levels. It should also be noted that 8-iso PGF2a  levels 
are also influenced by the glucose level itself 19）. In the 
current study, a tendency toward a positive correla-
tion between 8-iso PGF2a  and FPG in both groups 
was also found. Recently, Yamazaki et al, reported 
that the switch from glimepiride to repaglinide 
showed no difference in the HbA1c levels, and the 
8-iso PGF2a  levels were also not changed, although 
urinary 8-hydroxydeoxyguanosine（8-OHGd）（another 
marker of systemic oxidative stress）was significantly 
reduced 12）. It is difficult to interpret this result accu-
rately. However, the baseline HbA1c levels and the 
8-iso PGF2a  levels were higher in our study. In addi-
tion, in the study by Yamazaki et al., glimepiride 1 mg 
once daily was switched to repaglinide 0.25 mg three 
times daily. These differences may partially explain 
the positive result in the current study. On the other 
hand, the switch from mitiglinide to repaglinide did 
not change the 8-iso PGF2a  levels despite the stron-
ger effect on overall glycemic control by repaglinide 
compared with that by mitiglinide. Apart from the 
issues relating to the small number of patients as one 
of the reason for this result, it should also be consid-
ered that the 8-iso PGF2a  levels at baseline were 
already lower（although not statistically significant）
when the glimepiride was switched to repaglinide 
even if 8-iso PGF2a  levels are influenced by the glu-
cose level itself. We speculate that the possible pla-
narization of glucose variation by mitiglinide com-
pared with that by glimepiride might have resulted in 
the improvement of oxidative stress reflected by the 
low levels at baseline of 8-iso PGF2a . In this study, 
the 8-iso PGF2a  levels at baseline in patients treated 
with mitiglinide were similar compared with that in 
healthy subjects. Importantly, although repaglinide 
therapy after the switch from glimepiride significantly 
reduced the 8-iso PGF2a  levels, the levels were still 
Table 3　 Correlation between 8-iso-PGF2a  and glycemic 
control markers at baseline, or between
difference in 8-iso-PGF2a  and that in glycemic control 
markers before and after the change to repaglinide
Glimepiride
Baseline 8-isoPGF2a  -FPG 0.5298 0.0936　
Baseline 8-isoPGF2a- HbA1c 0.1722 0.6125　
Δ8-isoPGF2a-ΔFPG 0.2881 0.3903　
Δ8-isoPGF2a-ΔHbA1c 0.1182 0.7293　
Mitiglinide
Baseline 8-isoPGF2a- FPG 0.5937 0.2141　
Baseline 8-isoPGF2a- HbA1c 0.3295 0.5235　
Δ8-isoPGF2a-ΔFPG 0.9016 0.0141＊
Δ8-isoPGF2a-ΔHbA1c 0.8695 0.0244＊
Glimepiride：patients-group changed from glibenclamide 
to repaglinide,
Mitiglinide：patients-group changed from mitiglinide to 
repaglinide, FPG：fasting plasma glucose（mg/dL）, 
HbA1c：hemoglobin A1c（％）, 8-iso-PGFa：8-iso-prosta-
glandin F2a（pg/g.Cr）.
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high compared with that in healthy subjects. Because 
mitiglinide was administrated for a long-term period 
over 3 months in most patients, this may explain its 
possible strong effect on oxidative stress. We previ-
ously reported that short-acting insulin therapy 
before each meal over about 10 days did not change 
the 8-iso PGF2a  levels 20）. This may also suggest that 
long-term treatment is important for the improve-
ment of the 8-iso PGF2a  levels when the treatment 
for PPPG was targeted. Taken together, it may be 
possible that relatively low levels of 8-iso PGF2a  at 
baseline weakened the potentially strong effect of rep-
aglinide on oxidative stress.
In the current study, the significant correlation 
between the difference in the 8-iso PGF2a  levels and 
that in FPG or in HbA1c levels 3 months after the 
switch to repaglinide was observed only in the miti-
glinide-treated group. It is speculated that the switch 
from mitiglinide had less effect on the degree of glu-
cose-variation compared with that from glimepiride. 
Therefore, since the 8-iso PGF2a  levels are not only 
influenced by glucose-variation but also by the glu-
cose level itself, it may be possible that the 8-iso 
PGF2a  levels were more strongly influenced by the 
glucose level in the mitiglinide-treated group when 
compared with the glimepiride-treated group.
In the current study, HOMA-IR was basically un-
changed by the switch from either glimepiride or 
mitiglinide to repaglinide, suggesting that these drugs 
are all active on insulin secretion. On the other hand, 
there was a tendency toward a decrease of HOMA-b  
in the group switching from glimepiride to repa-
glinide. This appears to be reasonable when it is con-
sidered that repaglinide is a short-acting drug, and 
the significant decrease of HbA1c after the switch to 
repaglinide may be explained by its possible stronger 
effect on postprandial glucose.
This study has several limitations. First, this study 
was a single arm study with a relatively small num-
ber of patients. Second, we could not evaluate PPPG 
in this study. Finally, the observation periods may 
have been relatively short. Further studies are war-
ranted to investigate the possible beneficial effect on 
oxidative stress of repaglinide in patients with type 2 
diabetes.
In conclusion, we investigated the effect of switch-
ing from either a low dose sulfonyl glimepiride treat-
ment（1 mg once daily）or a glinide mitiglinide treat-
ment（10 mg three times daily）to repaglinide 0.5 mg 
three times daily, on glycemic control and on oxida-
tive stress as determined by urinary 8-iso-prostaglan-
din F2a  levels. Despite the significant decrease of 
HbA1c in both groups, the 8-iso-prostaglandin F2a  
levels were decreased only in the group that switched 
from glimepiride to repaglinide. Possible improvement 
of glucose variability by repaglinide in addition to the 
potentially strong effect of this agent on glycemic con-
trol may partially explain these results.
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